JP2017529852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529852A5 JP2017529852A5 JP2017516368A JP2017516368A JP2017529852A5 JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5 JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- respond
- egfr
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 17
- 229940121647 egfr inhibitor Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 claims 5
- 108091070501 miRNA Proteins 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 239000013610 patient sample Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306490.5 | 2014-09-26 | ||
| EP14306490.5A EP3000895A1 (en) | 2014-09-26 | 2014-09-26 | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| PCT/EP2015/072095 WO2016046365A1 (en) | 2014-09-26 | 2015-09-25 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529852A JP2017529852A (ja) | 2017-10-12 |
| JP2017529852A5 true JP2017529852A5 (https=) | 2018-10-25 |
Family
ID=51663116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516368A Withdrawn JP2017529852A (ja) | 2014-09-26 | 2015-09-25 | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170298442A1 (https=) |
| EP (2) | EP3000895A1 (https=) |
| JP (1) | JP2017529852A (https=) |
| KR (1) | KR20170086469A (https=) |
| CN (1) | CN107075583A (https=) |
| AU (1) | AU2015323744A1 (https=) |
| BR (1) | BR112017005421A2 (https=) |
| CA (1) | CA2961434A1 (https=) |
| MX (1) | MX2017003832A (https=) |
| WO (1) | WO2016046365A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2749651T3 (es) | 2015-02-11 | 2020-03-23 | Region Midtjylland | Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina |
| ES2724404T3 (es) * | 2015-02-27 | 2019-09-10 | Qiagen Gmbh | Un procedimiento basado en microARN para evaluar el pronóstico de un paciente de cáncer de próstata |
| CN108034727B (zh) * | 2018-01-18 | 2021-05-28 | 四川大学华西医院 | 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途 |
| KR102480430B1 (ko) * | 2020-10-21 | 2022-12-21 | 순천향대학교 산학협력단 | 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도 |
| CN119303090B (zh) * | 2024-10-15 | 2025-06-20 | 中国医学科学院北京协和医院 | miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20120095030A1 (en) | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| MX2011013578A (es) * | 2009-06-19 | 2012-01-20 | Merck Patent Gmbh | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CA2856594A1 (en) | 2011-11-25 | 2013-05-30 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| CN104046679B (zh) * | 2013-03-11 | 2016-08-24 | 戴勇 | 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用 |
-
2014
- 2014-09-26 EP EP14306490.5A patent/EP3000895A1/en not_active Withdrawn
-
2015
- 2015-09-25 CA CA2961434A patent/CA2961434A1/en not_active Abandoned
- 2015-09-25 KR KR1020177009944A patent/KR20170086469A/ko not_active Withdrawn
- 2015-09-25 US US15/513,223 patent/US20170298442A1/en not_active Abandoned
- 2015-09-25 EP EP15767530.7A patent/EP3198028B1/en not_active Not-in-force
- 2015-09-25 AU AU2015323744A patent/AU2015323744A1/en not_active Abandoned
- 2015-09-25 BR BR112017005421A patent/BR112017005421A2/pt not_active IP Right Cessation
- 2015-09-25 CN CN201580051832.9A patent/CN107075583A/zh active Pending
- 2015-09-25 JP JP2017516368A patent/JP2017529852A/ja not_active Withdrawn
- 2015-09-25 WO PCT/EP2015/072095 patent/WO2016046365A1/en not_active Ceased
- 2015-09-25 MX MX2017003832A patent/MX2017003832A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533960A5 (https=) | ||
| Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
| Lohaus et al. | HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) | |
| Bossi et al. | Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: a review of the literature | |
| Lechner et al. | Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma | |
| JP2017529852A5 (https=) | ||
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| WO2015052583A3 (en) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer | |
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| Gao et al. | IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma | |
| EA201500327A1 (ru) | Неинвазивное определение метилома плода или опухоли по плазме | |
| RU2018104570A (ru) | Экспрессия fgfr и чувствительность к ингибитору fgfr | |
| NZ627864A (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
| JP6489658B2 (ja) | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Karagiannis et al. | IGF-IEc expression is associated with advanced differentiated thyroid cancer | |
| KR102241063B1 (ko) | 예측성 바이오마커에 대한 검정법 | |
| KR20170086469A (ko) | Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 | |
| Schweiger et al. | Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling | |
| Linardou et al. | Prognostic significance of VEGFC and VEGFR1 mRNA expression according to HER2 status in breast cancer: a study of primary tumors from patients with high-risk early breast cancer participating in a randomized Hellenic Cooperative Oncology Group Trial | |
| An et al. | Association of E2F3 expression with clinicopathological features of Wilms’ tumors | |
| Zhou et al. | Increased expression of long non-coding RNA SBDSP1 correlates with poor survival in colorectal cancer | |
| Liefaard et al. | RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer | |
| Ilie et al. | BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer |